Glycolic Acid

Evidence Level: L5

Predicted Indications: 10

Glycolic Acid

Pharmacist Assessment Report

Glycolic Acid: From an Unspecified Original Indication to Atypical Coarctation of Aorta

One-Sentence Summary

Glycolic acid is currently marketed in India as an ingredient of a topical face wash, and no approved medical indication is recorded for it. The TxGNN model (deep learning) predicts it may be relevant to atypical coarctation of aorta, but this score may reflect similarities the model learned between related diseases, not biological evidence, and it is supported by 0 clinical trials and only indirect preclinical literature. The retrieved papers concern glycolic acid-containing polymers (PGA, PLGA) used as biomaterials, not glycolic acid as an active drug.

Quick Overview

Item	Content
Original Indication	Not specified (the registered product is a cosmetic-type foaming face wash with no approved indication text)
Predicted New Indication	Esophageal disease (the highest-ranked prediction, atypical coarctation of aorta, has no supporting evidence at all; esophageal disease is the highest-ranked prediction with any literature)
TxGNN Prediction Score	0.9969 (esophageal disease); 0.9972 for the top-ranked atypical coarctation of aorta
Evidence Level	L5 (esophageal disease); L5 for the top-ranked prediction
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Glycolic acid is an alpha-hydroxy acid, and the only registered product in India is a topical face wash. No original medical indication is documented, so a link between a prior therapeutic use and the predicted indication cannot be drawn.

The retrieved literature on esophageal disease concerns polyglycolic acid (PGA) sheets and PLGA-based materials. These are used as stent coatings, scaffolds, and drug carriers to prevent or treat esophageal stricture. Glycolic acid is only a degradation monomer of these polymers. The therapeutic effect in these studies comes from the device, the carrier, or the loaded drug (paclitaxel, bFGF, triamcinolone), not from glycolic acid itself. The mechanistic link is therefore indirect and does not support a therapeutic indication for glycolic acid.

The other top predictions, including non-syndromic esophageal malformation, esophageal disease, potassium deficiency disease, sclerosing cholangitis, and several familial hyperinsulinism disorders, have no identifiable pharmacological rationale and no supporting trials or literature. Their high scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The literature below was retrieved for esophageal disease. All items are preclinical or otherwise low-tier, and several are off-topic.

PMID	Year	Type	Journal	Key Findings
37635203	2023	Experimental (PGA sheet, pigs)	J Gastroenterol	Polyglycolic acid sheets with bFGF tested to prevent stricture after esophageal endoscopic submucosal dissection
35487426	2022	Preclinical	Acta Biomater	Biodegradable paclitaxel-PLGA-coated magnesium stent for benign esophageal stricture; the coating increased radial force
33543561	2021	Preclinical	Cell Prolif	Chitosan-collagen scaffold loaded with PLGA/triamcinolone microspheres to reduce stenosis after endoscopic dissection
28556975	2017	Case report	Dig Endosc	Polyglycolic acid mesh combined with a gastropexy device to close gastrocutaneous fistulas
36238233	2022	Bibliometric analysis	Front Public Health	Research trends in endoscopic submucosal dissection; not specific to glycolic acid
29808844	2018	Preclinical (off-topic)	Nanoscale	PLGA nanoparticles delivering a ruthenium radiosensitizer to oesophageal cancer cells
24996905	2014	Genetic study (off-topic)	J Med Genet	HAO1 mutations cause isolated glycolic aciduria; unrelated to esophageal therapy
41135390	2026	Preclinical (off-topic)	Drug Resist Updat	PROTAC delivery for drug-resistant lung cancer

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
94773	Glucy Foaming Face Wash	Bottle of 100 ml face wash	Not specified

Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found, and no contraindication links were identified in the knowledge graph.

Conclusion and Next Steps

Decision: Hold

Rationale: The predictions rest on TxGNN model (deep learning) scores alone, which may reflect similarities the model learned between related diseases, not biological evidence. The only supporting literature for esophageal disease concerns glycolic acid-based polymers as device or carrier materials, not glycolic acid as a drug. The only registered product is a topical face wash, so there is no established therapeutic use to build on.

To proceed, the following is needed:

Mechanism of action data for glycolic acid
Package insert warnings and contraindications
Evidence that glycolic acid itself, rather than PGA/PLGA materials, has activity in the predicted disease
Assessment of route compatibility, since the only marketed form is topical and the predicted indications would likely require a different route
Preclinical studies to test any plausible mechanistic hypothesis before further evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.